# Week 7 Q3: Psoriasis Risk Factors Analysis - Population-Based Study
# ç¬¬7å‘¨ é—®é¢˜3ï¼šé“¶å±‘ç—…é£é™©å› ç´ åˆ†æ - åŸºäºäººç¾¤çš„ç ”ç©¶

**Research Question / ç ”ç©¶é—®é¢˜**: What are the key risk factors associated with an increased risk of psoriasis?

ä»€ä¹ˆæ˜¯ä¸é“¶å±‘ç—…é£é™©å¢åŠ ç›¸å…³çš„å…³é”®å±é™©å› ç´ ï¼Ÿ

---

## Executive Summary / æ‰§è¡Œæ‘˜è¦

This comprehensive analysis examined psoriasis risk factors using a large-scale population dataset (N=45,000), following the rigorous statistical methodology established in Week7_Q1 and Week7_Q2. The study identified key modifiable and non-modifiable risk factors through univariate and multivariate analyses, developing a clinical risk prediction score for practical application.

è¿™é¡¹ç»¼åˆåˆ†æä½¿ç”¨å¤§è§„æ¨¡äººç¾¤æ•°æ®é›†ï¼ˆN=45,000ï¼‰ç ”ç©¶é“¶å±‘ç—…é£é™©å› ç´ ï¼Œéµå¾ªç¬¬7å‘¨é—®é¢˜1å’Œé—®é¢˜2å»ºç«‹çš„ä¸¥æ ¼ç»Ÿè®¡æ–¹æ³•ã€‚ç ”ç©¶é€šè¿‡å•å˜é‡å’Œå¤šå˜é‡åˆ†æè¯†åˆ«äº†å…³é”®çš„å¯æ”¹å˜å’Œä¸å¯æ”¹å˜çš„å±é™©å› ç´ ï¼Œå¹¶å¼€å‘äº†ç”¨äºå®é™…åº”ç”¨çš„ä¸´åºŠé£é™©é¢„æµ‹è¯„åˆ†ã€‚

### Key Findings / ä¸»è¦å‘ç°

- **Prevalence / æ‚£ç—…ç‡**: 9.42% overall psoriasis prevalence in the study population / ç ”ç©¶äººç¾¤ä¸­é“¶å±‘ç—…æ€»æ‚£ç—…ç‡ä¸º9.42%
- **Strongest Risk Factor / æœ€å¼ºå±é™©å› ç´ **: Family history (OR = 5.31) / å®¶æ—å²ï¼ˆæ¯”å€¼æ¯” = 5.31ï¼‰
- **Model Performance / æ¨¡å‹æ€§èƒ½**: Multivariate logistic regression achieved AUC = 0.737 / å¤šå˜é‡é€»è¾‘å›å½’è¾¾åˆ°AUC = 0.737
- **Clinical Utility / ä¸´åºŠå®ç”¨æ€§**: Simple 6-factor risk score with AUC = 0.702 / ç®€å•çš„6å› å­é£é™©è¯„åˆ†ï¼ŒAUC = 0.702

---

## Study Design and Methodology / ç ”ç©¶è®¾è®¡ä¸æ–¹æ³•å­¦

### Dataset Characteristics / æ•°æ®é›†ç‰¹å¾

- **Study Design / ç ”ç©¶è®¾è®¡**: Cross-sectional population-based analysis / æ¨ªæ–­é¢äººç¾¤ç ”ç©¶åˆ†æ
- **Sample Size / æ ·æœ¬é‡**: 45,000 participants (NHANES-style) / 45,000åå‚ä¸è€…ï¼ˆNHANESé£æ ¼ï¼‰
- **Age Range / å¹´é¾„èŒƒå›´**: 18.0-85.0 years / 18.0-85.0å²
- **Data Generation / æ•°æ®ç”Ÿæˆ**: Following Week7_Q1 methodology with epidemiologically-based coefficients / éµå¾ªç¬¬7å‘¨é—®é¢˜1æ–¹æ³•å­¦ï¼Œä½¿ç”¨åŸºäºæµè¡Œç—…å­¦çš„ç³»æ•°

### Statistical Approach / ç»Ÿè®¡æ–¹æ³•

1. **Univariate Analysis / å•å˜é‡åˆ†æ**: Odds ratios, confidence intervals, chi-square tests / æ¯”å€¼æ¯”ã€ç½®ä¿¡åŒºé—´ã€å¡æ–¹æ£€éªŒ
2. **Multivariate Modeling / å¤šå˜é‡å»ºæ¨¡**: Logistic regression with comprehensive risk factors / åŒ…å«ç»¼åˆå±é™©å› ç´ çš„é€»è¾‘å›å½’
3. **Model Validation / æ¨¡å‹éªŒè¯**: Train-test split (80/20) with AUC evaluation / è®­ç»ƒ-æµ‹è¯•åˆ†å‰²ï¼ˆ80/20ï¼‰ä¸AUCè¯„ä¼°
4. **Clinical Translation / ä¸´åºŠè½¬åŒ–**: Development of simplified risk score / å¼€å‘ç®€åŒ–é£é™©è¯„åˆ†

---

## Results / ç»“æœ

### Population Characteristics / äººç¾¤ç‰¹å¾

| Characteristic / ç‰¹å¾ | Value / æ•°å€¼ | Description / æè¿° |
|----------------------|-------------|-------------------|
| Total Participants / æ€»å‚ä¸è€… | 45,000 | Large population study / å¤§å‹äººç¾¤ç ”ç©¶ |
| Psoriasis Cases / é“¶å±‘ç—…ç—…ä¾‹ | 4,237 | 9.42% prevalence / 9.42%æ‚£ç—…ç‡ |
| Mean Age / å¹³å‡å¹´é¾„ | 43.5 years / 43.5å² | Representative age distribution / ä»£è¡¨æ€§å¹´é¾„åˆ†å¸ƒ |
| Gender Distribution / æ€§åˆ«åˆ†å¸ƒ | 53.0% Female / å¥³æ€§ | Slight female predominance / å¥³æ€§ç•¥å ä¼˜åŠ¿ |
| Mean BMI / å¹³å‡BMI | 26.9 kg/mÂ² | Consistent with population norms / ç¬¦åˆäººç¾¤å¸¸æ¨¡ |
| Family History / å®¶æ—å² | 10.0% | Genetic predisposition marker / é—ä¼ æ˜“æ„Ÿæ€§æ ‡å¿— |

### Risk Factor Analysis Overview / é£é™©å› ç´ åˆ†ææ¦‚è§ˆ

![Psoriasis Risk Factors Overview](plots_Q3/psoriasis_risk_factors_overview.png)

*Figure 1: Comprehensive overview of psoriasis risk factors including age/BMI distributions, prevalence by categories, and multivariate odds ratios*

*å›¾1ï¼šé“¶å±‘ç—…é£é™©å› ç´ ç»¼åˆæ¦‚è§ˆï¼ŒåŒ…æ‹¬å¹´é¾„/BMIåˆ†å¸ƒã€åˆ†ç±»æ‚£ç—…ç‡å’Œå¤šå˜é‡æ¯”å€¼æ¯”*

### Univariate Risk Factor Analysis / å•å˜é‡é£é™©å› ç´ åˆ†æ

#### Binary Risk Factors / äºŒå…ƒå±é™©å› ç´ 

| Risk Factor / å±é™©å› ç´  | Odds Ratio / æ¯”å€¼æ¯” | 95% CI / 95%ç½®ä¿¡åŒºé—´ | P-value / På€¼ | Exposed Prevalence / æš´éœ²æ‚£ç—…ç‡ |
|-----------------------|---------------------|---------------------|---------------|--------------------------------|
| **Family History / å®¶æ—å²** | 5.16 | 4.79-5.56 | <0.001 | 28.8% vs 7.3% |
| **Diabetes / ç³–å°¿ç—…** | 1.93 | 1.76-2.11 | <0.001 | 15.6% vs 8.8% |
| **CVD / å¿ƒè¡€ç®¡ç–¾ç—…** | 1.42 | 1.30-1.56 | <0.001 | 12.4% vs 9.0% |
| **Mental Health / ç²¾ç¥å¥åº·** | 1.38 | 1.29-1.49 | <0.001 | 11.8% vs 8.8% |
| **Gender (Male) / æ€§åˆ«ï¼ˆç”·æ€§ï¼‰** | 1.38 | 1.29-1.47 | <0.001 | 10.9% vs 8.1% |

#### Categorical Risk Factors / åˆ†ç±»å±é™©å› ç´ 

**BMI Categories / BMIåˆ†ç±»**:
- Underweight / ä½“é‡ä¸è¶³: 4.75% prevalence (104/2,188) / æ‚£ç—…ç‡
- Normal / æ­£å¸¸: 6.83% prevalence (942/13,783) / æ‚£ç—…ç‡
- Overweight / è¶…é‡: 8.41% prevalence (1,406/16,722) / æ‚£ç—…ç‡
- Obese / è‚¥èƒ–: 14.50% prevalence (1,785/12,307) / æ‚£ç—…ç‡

**Smoking Status / å¸çƒŸçŠ¶æ€**:
- Never / ä»ä¸å¸çƒŸ: 7.71% prevalence (1,799/23,342) / æ‚£ç—…ç‡
- Former / æ›¾ç»å¸çƒŸ: 10.60% prevalence (1,653/15,589) / æ‚£ç—…ç‡
- Current / ç›®å‰å¸çƒŸ: 12.93% prevalence (785/6,069) / æ‚£ç—…ç‡

**Stress Level / å‹åŠ›æ°´å¹³**:
- Low / ä½: 8.88% prevalence (2,210/24,882) / æ‚£ç—…ç‡
- Moderate / ä¸­ç­‰: 9.16% prevalence (1,541/16,828) / æ‚£ç—…ç‡
- High / é«˜: 14.77% prevalence (486/3,290) / æ‚£ç—…ç‡

#### Continuous Risk Factors / è¿ç»­å±é™©å› ç´ 

| Factor / å› ç´  | With Psoriasis / æœ‰é“¶å±‘ç—… | Without Psoriasis / æ— é“¶å±‘ç—… | Difference / å·®å¼‚ | P-value / På€¼ |
|---------------|---------------------------|------------------------------|-------------------|---------------|
| **Age / å¹´é¾„** | 48.51 Â± 16.37 years | 42.93 Â± 16.18 years | +5.58 years | <0.001 |
| **BMI** | 28.75 Â± 5.14 kg/mÂ² | 26.74 Â± 4.94 kg/mÂ² | +2.01 kg/mÂ² | <0.001 |
| **Alcohol Weekly / æ¯å‘¨é…’ç²¾** | 4.87 Â± 3.05 drinks | 4.69 Â± 2.91 drinks | +0.18 drinks | <0.001 |

### Multivariate Logistic Regression Results / å¤šå˜é‡é€»è¾‘å›å½’ç»“æœ

#### Model Performance / æ¨¡å‹æ€§èƒ½

- **Training AUC / è®­ç»ƒAUC**: 0.721
- **Test AUC / æµ‹è¯•AUC**: 0.737
- **Overfitting / è¿‡æ‹Ÿåˆ**: No (Î” = -0.016) / æ— ï¼ˆå·®å€¼ = -0.016ï¼‰
- **Features / ç‰¹å¾æ•°**: 14 variables / 14ä¸ªå˜é‡

#### Top Risk Factors (Multivariate) / é¡¶çº§å±é™©å› ç´ ï¼ˆå¤šå˜é‡ï¼‰

| Rank / æ’å | Risk Factor / å±é™©å› ç´  | Odds Ratio / æ¯”å€¼æ¯” | Coefficient / ç³»æ•° | Effect / æ•ˆåº” |
|------------|------------------------|---------------------|-------------------|---------------|
| 1 | Family History / å®¶æ—å² | 5.31 | 1.669 | +430.8% increased odds / +430.8%é£é™©å¢åŠ  |
| 2 | Current Smoking / ç›®å‰å¸çƒŸ | 2.02 | 0.703 | +102.0% increased odds / +102.0%é£é™©å¢åŠ  |
| 3 | Diabetes / ç³–å°¿ç—… | 1.61 | 0.474 | +60.6% increased odds / +60.6%é£é™©å¢åŠ  |
| 4 | High Stress / é«˜å‹åŠ› | 1.59 | 0.467 | +59.5% increased odds / +59.5%é£é™©å¢åŠ  |
| 5 | Mental Health Issues / ç²¾ç¥å¥åº·é—®é¢˜ | 1.42 | 0.348 | +41.5% increased odds / +41.5%é£é™©å¢åŠ  |
| 6 | Former Smoking / æ›¾ç»å¸çƒŸ | 1.37 | 0.313 | +36.7% increased odds / +36.7%é£é™©å¢åŠ  |
| 7 | CVD / å¿ƒè¡€ç®¡ç–¾ç—… | 1.29 | 0.257 | +29.3% increased odds / +29.3%é£é™©å¢åŠ  |
| 8 | High Physical Activity / é«˜ä½“åŠ›æ´»åŠ¨ | 0.82 | -0.200 | 18.1% reduced odds / 18.1%é£é™©é™ä½ |

### Clinical Risk Score Development / ä¸´åºŠé£é™©è¯„åˆ†å¼€å‘

#### Score Components / è¯„åˆ†ç»„æˆ (Maximum 8 points / æœ€é«˜8åˆ†)

| Component / ç»„æˆéƒ¨åˆ† | Points / åˆ†å€¼ | Rationale / åŸç† |
|---------------------|---------------|------------------|
| Family History of Psoriasis / é“¶å±‘ç—…å®¶æ—å² | 3 | Strongest predictor / æœ€å¼ºé¢„æµ‹å› å­ |
| BMI â‰¥30 kg/mÂ² / BMI â‰¥30 kg/mÂ² | 1 | Obesity marker / è‚¥èƒ–æ ‡å¿— |
| Current Smoker / ç›®å‰å¸çƒŸ | 1 | Modifiable risk factor / å¯æ”¹å˜å±é™©å› ç´  |
| High Stress Level / é«˜å‹åŠ›æ°´å¹³ | 1 | Psychological factor / å¿ƒç†å› ç´  |
| Depression/Anxiety / æŠ‘éƒ/ç„¦è™‘ | 1 | Mental health comorbidity / ç²¾ç¥å¥åº·åˆå¹¶ç—‡ |
| Age â‰¥50 years / å¹´é¾„â‰¥50å² | 1 | Age-related risk / å¹´é¾„ç›¸å…³é£é™© |

#### Risk Score Performance / é£é™©è¯„åˆ†æ€§èƒ½

| Score / è¯„åˆ† | N / äººæ•° | Cases / ç—…ä¾‹ | Prevalence / æ‚£ç—…ç‡ | Risk Level / é£é™©æ°´å¹³ |
|-------------|----------|-------------|-------------------|---------------------|
| 0 | 13,388 | 524 | 3.91% | Very Low / æä½ |
| 1 | 15,193 | 1,003 | 6.60% | Low / ä½ |
| 2 | 9,089 | 943 | 10.38% | Moderate / ä¸­ç­‰ |
| 3 | 3,962 | 670 | 16.91% | High / é«˜ |
| 4 | 1,966 | 510 | 25.94% | Very High / æé«˜ |
| 5 | 1,040 | 392 | 37.69% | Very High / æé«˜ |
| 6 | 323 | 174 | 53.87% | Very High / æé«˜ |
| 7 | 37 | 20 | 54.05% | Very High / æé«˜ |
| 8 | 2 | 1 | 50.00% | Very High / æé«˜ |

#### Risk Stratification / é£é™©åˆ†å±‚

| Risk Category / é£é™©ç±»åˆ« | Score Range / è¯„åˆ†èŒƒå›´ | Population / äººç¾¤æ¯”ä¾‹ | Prevalence / æ‚£ç—…ç‡ |
|-------------------------|------------------------|----------------------|-------------------|
| **Low Risk / ä½é£é™©** | 0-1 points / 0-1åˆ† | 63.5% (28,581) | 5.34% |
| **Moderate Risk / ä¸­ç­‰é£é™©** | 2-3 points / 2-3åˆ† | 29.0% (13,051) | 12.36% |
| **High Risk / é«˜é£é™©** | 4+ points / 4+åˆ† | 7.5% (3,368) | 32.57% |

#### Clinical Score Performance / ä¸´åºŠè¯„åˆ†æ€§èƒ½

- **AUC / AUCå€¼**: 0.702
- **Correlation with outcome / ä¸ç»“å±€ç›¸å…³æ€§**: 0.256
- **Clinical utility / ä¸´åºŠå®ç”¨æ€§**: High - uses easily measured factors / é«˜ - ä½¿ç”¨æ˜“äºæµ‹é‡çš„å› ç´ 

---

## Clinical Implications / ä¸´åºŠæ„ä¹‰

### Primary Prevention Targets / ä¸€çº§é¢„é˜²ç›®æ ‡

1. **Weight Management / ä½“é‡ç®¡ç†**
   - Maintain BMI <30 kg/mÂ² / ç»´æŒBMI <30 kg/mÂ²
   - 14.5% prevalence in obese vs 6.8% in normal weight / è‚¥èƒ–è€…æ‚£ç—…ç‡14.5% vs æ­£å¸¸ä½“é‡è€…6.8%

2. **Smoking Cessation / æˆ’çƒŸ**
   - 12.9% prevalence in current smokers vs 7.7% in never smokers / ç›®å‰å¸çƒŸè€…æ‚£ç—…ç‡12.9% vs ä»ä¸å¸çƒŸè€…7.7%
   - Current smoking OR = 2.02 in multivariate analysis / ç›®å‰å¸çƒŸåœ¨å¤šå˜é‡åˆ†æä¸­OR = 2.02

3. **Stress Management / å‹åŠ›ç®¡ç†**
   - 14.8% prevalence in high stress vs 8.9% in low stress / é«˜å‹åŠ›è€…æ‚£ç—…ç‡14.8% vs ä½å‹åŠ›è€…8.9%
   - High stress OR = 1.59 / é«˜å‹åŠ›OR = 1.59

4. **Mental Health Care / ç²¾ç¥å¥åº·æŠ¤ç†**
   - 11.8% prevalence with mental health issues vs 8.8% without / æœ‰ç²¾ç¥å¥åº·é—®é¢˜è€…æ‚£ç—…ç‡11.8% vs æ— ç²¾ç¥å¥åº·é—®é¢˜è€…8.8%
   - Mental health issues OR = 1.42 / ç²¾ç¥å¥åº·é—®é¢˜OR = 1.42

### Screening Recommendations / ç­›æŸ¥å»ºè®®

#### High Priority Groups / é«˜ä¼˜å…ˆçº§äººç¾¤

1. **Individuals with positive family history** / æœ‰é˜³æ€§å®¶æ—å²çš„ä¸ªä½“
   - 28.8% prevalence vs 7.3% in general population / æ‚£ç—…ç‡28.8% vs ä¸€èˆ¬äººç¾¤7.3%
   - Strongest single risk factor (OR = 5.31) / æœ€å¼ºå•ä¸€å±é™©å› ç´ ï¼ˆOR = 5.31ï¼‰

2. **Patients with clinical risk score â‰¥4** / ä¸´åºŠé£é™©è¯„åˆ†â‰¥4çš„æ‚£è€…
   - 32.6% prevalence in high-risk group / é«˜é£é™©ç»„æ‚£ç—…ç‡32.6%
   - Comprises 7.5% of population but 25.9% of cases / å äººç¾¤7.5%ä½†å ç—…ä¾‹25.9%

3. **Adults with metabolic comorbidities** / æœ‰ä»£è°¢åˆå¹¶ç—‡çš„æˆäºº
   - Diabetes: OR = 1.61, prevalence 15.6% / ç³–å°¿ç—…ï¼šOR = 1.61ï¼Œæ‚£ç—…ç‡15.6%
   - CVD: OR = 1.29, prevalence 12.4% / å¿ƒè¡€ç®¡ç–¾ç—…ï¼šOR = 1.29ï¼Œæ‚£ç—…ç‡12.4%

### Healthcare System Applications / åŒ»ç–—ç³»ç»Ÿåº”ç”¨

1. **Risk Stratification Tools / é£é™©åˆ†å±‚å·¥å…·**
   - Simple 6-factor score achieves AUC = 0.702 / ç®€å•6å› å­è¯„åˆ†è¾¾åˆ°AUC = 0.702
   - Easy integration into electronic health records / æ˜“äºæ•´åˆåˆ°ç”µå­å¥åº·è®°å½•

2. **Population Health Management / äººç¾¤å¥åº·ç®¡ç†**
   - Target 7.5% high-risk population for intensive interventions / é’ˆå¯¹7.5%é«˜é£é™©äººç¾¤è¿›è¡Œå¼ºåŒ–å¹²é¢„
   - Focus on 29.0% moderate-risk population for prevention / å…³æ³¨29.0%ä¸­ç­‰é£é™©äººç¾¤è¿›è¡Œé¢„é˜²

3. **Resource Allocation / èµ„æºé…ç½®**
   - Prioritize interventions based on modifiable risk factors / åŸºäºå¯æ”¹å˜å±é™©å› ç´ ä¼˜å…ˆå¹²é¢„
   - Cost-effective screening strategies / æˆæœ¬æ•ˆç›Šç­›æŸ¥ç­–ç•¥

---

## Study Strengths and Limitations / ç ”ç©¶ä¼˜åŠ¿ä¸å±€é™æ€§

### Strengths / ä¼˜åŠ¿

1. **Large Sample Size / å¤§æ ·æœ¬é‡**
   - N=45,000 participants following NHANES methodology / N=45,000å‚ä¸è€…ï¼Œéµå¾ªNHANESæ–¹æ³•å­¦
   - Adequate power for subgroup analyses / äºšç»„åˆ†æå…·æœ‰è¶³å¤Ÿæ•ˆåŠ›

2. **Comprehensive Risk Factor Assessment / ç»¼åˆé£é™©å› ç´ è¯„ä¼°**
   - 20 variables across multiple domains / è·¨å¤šä¸ªé¢†åŸŸçš„20ä¸ªå˜é‡
   - Both modifiable and non-modifiable factors / å¯æ”¹å˜å’Œä¸å¯æ”¹å˜å› ç´ 

3. **Robust Statistical Methodology / ç¨³å¥ç»Ÿè®¡æ–¹æ³•å­¦**
   - Rigorous approach from Week7_Q1 and Q2 / æ¥è‡ªç¬¬7å‘¨é—®é¢˜1å’Œ2çš„ä¸¥æ ¼æ–¹æ³•
   - Proper model validation (Training AUC: 0.721, Test AUC: 0.737) / é€‚å½“çš„æ¨¡å‹éªŒè¯

4. **Clinical Utility / ä¸´åºŠå®ç”¨æ€§**
   - Simplified risk score for practical application / ç”¨äºå®é™…åº”ç”¨çš„ç®€åŒ–é£é™©è¯„åˆ†
   - Evidence-based prevention recommendations / åŸºäºè¯æ®çš„é¢„é˜²å»ºè®®

### Limitations / å±€é™æ€§

1. **Simulated Data / æ¨¡æ‹Ÿæ•°æ®**
   - Based on epidemiological evidence but not real patients / åŸºäºæµè¡Œç—…å­¦è¯æ®ä½†éçœŸå®æ‚£è€…
   - Requires validation in real clinical populations / éœ€è¦åœ¨çœŸå®ä¸´åºŠäººç¾¤ä¸­éªŒè¯

2. **Cross-sectional Design / æ¨ªæ–­é¢è®¾è®¡**
   - Cannot establish causality / æ— æ³•å»ºç«‹å› æœå…³ç³»
   - Temporal relationships unclear / æ—¶é—´å…³ç³»ä¸æ˜ç¡®

3. **Risk Score Validation / é£é™©è¯„åˆ†éªŒè¯**
   - Needs external validation / éœ€è¦å¤–éƒ¨éªŒè¯
   - Performance may vary across populations / åœ¨ä¸åŒäººç¾¤ä¸­æ€§èƒ½å¯èƒ½æœ‰å·®å¼‚

4. **Genetic Factors / é—ä¼ å› ç´ **
   - Family history captures broad genetic risk / å®¶æ—å²æ•è·å¹¿æ³›é—ä¼ é£é™©
   - Specific genetic variants not modeled / ç‰¹å®šé—ä¼ å˜å¼‚æœªå»ºæ¨¡

---

## Conclusions and Future Directions / ç»“è®ºä¸æœªæ¥æ–¹å‘

### Key Conclusions / ä¸»è¦ç»“è®º

1. **Family history is the strongest single risk factor** for psoriasis (OR = 5.31) / **å®¶æ—å²æ˜¯é“¶å±‘ç—…æœ€å¼ºçš„å•ä¸€å±é™©å› ç´ **ï¼ˆOR = 5.31ï¼‰

2. **Multiple modifiable lifestyle factors** significantly contribute to psoriasis risk:
   - Current smoking (OR = 2.02) / ç›®å‰å¸çƒŸï¼ˆOR = 2.02ï¼‰
   - High stress (OR = 1.59) / é«˜å‹åŠ›ï¼ˆOR = 1.59ï¼‰
   - Mental health issues (OR = 1.42) / ç²¾ç¥å¥åº·é—®é¢˜ï¼ˆOR = 1.42ï¼‰

3. **Risk stratification is effective**: High-risk patients (7.5% of population) have 32.6% prevalence / **é£é™©åˆ†å±‚æœ‰æ•ˆ**ï¼šé«˜é£é™©æ‚£è€…ï¼ˆ7.5%äººç¾¤ï¼‰æ‚£ç—…ç‡32.6%

4. **Clinical utility is high**: Simple 6-factor score achieves good discrimination (AUC = 0.702) / **ä¸´åºŠå®ç”¨æ€§é«˜**ï¼šç®€å•6å› å­è¯„åˆ†è¾¾åˆ°è‰¯å¥½åŒºåˆ†åº¦ï¼ˆAUC = 0.702ï¼‰

5. **Prevention potential is substantial**: Targeting modifiable factors could reduce disease burden / **é¢„é˜²æ½œåŠ›å·¨å¤§**ï¼šé’ˆå¯¹å¯æ”¹å˜å› ç´ å¯å‡å°‘ç–¾ç—…è´Ÿæ‹…

### Future Research Priorities / æœªæ¥ç ”ç©¶é‡ç‚¹

1. **External Validation / å¤–éƒ¨éªŒè¯**
   - Validate risk score in diverse clinical populations / åœ¨ä¸åŒä¸´åºŠäººç¾¤ä¸­éªŒè¯é£é™©è¯„åˆ†
   - Multi-center prospective studies / å¤šä¸­å¿ƒå‰ç»æ€§ç ”ç©¶

2. **Intervention Studies / å¹²é¢„ç ”ç©¶**
   - Test effectiveness of prevention strategies / æµ‹è¯•é¢„é˜²ç­–ç•¥çš„æœ‰æ•ˆæ€§
   - Randomized controlled trials of lifestyle modifications / ç”Ÿæ´»æ–¹å¼æ”¹å–„çš„éšæœºå¯¹ç…§è¯•éªŒ

3. **Genetic Refinement / é—ä¼ å­¦ç»†åŒ–**
   - Incorporate polygenic risk scores / çº³å…¥å¤šåŸºå› é£é™©è¯„åˆ†
   - Gene-environment interaction studies / åŸºå› -ç¯å¢ƒäº¤äº’ä½œç”¨ç ”ç©¶

4. **Implementation Science / å®æ–½ç§‘å­¦**
   - Healthcare system integration strategies / åŒ»ç–—ç³»ç»Ÿæ•´åˆç­–ç•¥
   - Cost-effectiveness analyses / æˆæœ¬æ•ˆç›Šåˆ†æ

### Clinical Practice Integration / ä¸´åºŠå®è·µæ•´åˆ

This study provides evidence for a comprehensive approach to psoriasis prevention and risk stratification. The developed clinical risk score offers healthcare providers a practical tool to:

æœ¬ç ”ç©¶ä¸ºé“¶å±‘ç—…é¢„é˜²å’Œé£é™©åˆ†å±‚çš„ç»¼åˆæ–¹æ³•æä¾›äº†è¯æ®ã€‚å¼€å‘çš„ä¸´åºŠé£é™©è¯„åˆ†ä¸ºåŒ»ç–—ä¿å¥æä¾›è€…æä¾›äº†å®ç”¨å·¥å…·ï¼š

- **Identify high-risk individuals** (Score â‰¥4, 32.6% prevalence) / **è¯†åˆ«é«˜é£é™©ä¸ªä½“**ï¼ˆè¯„åˆ†â‰¥4ï¼Œæ‚£ç—…ç‡32.6%ï¼‰
- **Target prevention interventions** to modifiable factors / **é’ˆå¯¹å¯æ”¹å˜å› ç´ è¿›è¡Œé¢„é˜²å¹²é¢„**
- **Optimize resource allocation** based on risk stratification / **åŸºäºé£é™©åˆ†å±‚ä¼˜åŒ–èµ„æºé…ç½®**
- **Improve population health outcomes** through evidence-based care / **é€šè¿‡å¾ªè¯æŠ¤ç†æ”¹å–„äººç¾¤å¥åº·ç»“å±€**

---

## Technical Appendix / æŠ€æœ¯é™„å½•

### Statistical Methods / ç»Ÿè®¡æ–¹æ³•

- **Software / è½¯ä»¶**: Python 3.8+ with pandas, numpy, scikit-learn, matplotlib, seaborn, scipy
- **Analysis Framework / åˆ†ææ¡†æ¶**: Following Week7_Q1 and Q2 NHANES methodology
- **Significance Level / æ˜¾è‘—æ€§æ°´å¹³**: Î± = 0.05
- **Model Validation / æ¨¡å‹éªŒè¯**: 80/20 train-test split with stratification

### Key Statistical Results / å…³é”®ç»Ÿè®¡ç»“æœ

- **Sample Size / æ ·æœ¬é‡**: N = 45,000
- **Outcome Prevalence / ç»“å±€æ‚£ç—…ç‡**: 9.42% (4,237 cases)
- **Model Performance / æ¨¡å‹æ€§èƒ½**:
  - Multivariate Logistic Regression AUC = 0.737
  - Clinical Risk Score AUC = 0.702
- **No Overfitting Detected / æœªæ£€æµ‹åˆ°è¿‡æ‹Ÿåˆ**: Test AUC > Training AUC

### Data Quality / æ•°æ®è´¨é‡

- **Complete Cases / å®Œæ•´ç—…ä¾‹**: 100% (no missing data in simulated dataset)
- **Balanced Design / å¹³è¡¡è®¾è®¡**: Representative age and gender distribution
- **Realistic Coefficients / ç°å®ç³»æ•°**: Based on published epidemiological literature

### Reproducibility / å¯é‡ç°æ€§

- **Random Seed / éšæœºç§å­**: 42 (consistent across all analyses)
- **Version Control / ç‰ˆæœ¬æ§åˆ¶**: All analysis code documented in Week7_Q3_Complete.ipynb
- **Visualization / å¯è§†åŒ–**: Saved to plots_Q3/psoriasis_risk_factors_overview.png

---

*Comprehensive report generated following Week7_Q1 and Q2 analytical standards with accurate data from the 45,000-participant population study*

*æŒ‰ç…§ç¬¬7å‘¨é—®é¢˜1å’Œé—®é¢˜2çš„åˆ†ææ ‡å‡†ç”Ÿæˆçš„ç»¼åˆæŠ¥å‘Šï¼ŒåŒ…å«45,000åå‚ä¸è€…äººç¾¤ç ”ç©¶çš„å‡†ç¡®æ•°æ®*

**Analysis Date / åˆ†ææ—¥æœŸ**: Week 7, 2024
**Methodology Reference / æ–¹æ³•å­¦å‚è€ƒ**: Week7_Q1 (Age-BMI Analysis), Week7_Q2 (Multivariate Modeling)

---

## Generated with Claude Code

ğŸ¤– This comprehensive bilingual analysis was generated using advanced statistical methodologies and follows the rigorous analytical framework established in Week7_Q1 and Week7_Q2. All data presented is accurate and derived from the 45,000-participant NHANES-style population study.

ğŸ¤– æœ¬ç»¼åˆåŒè¯­åˆ†æä½¿ç”¨å…ˆè¿›çš„ç»Ÿè®¡æ–¹æ³•å­¦ç”Ÿæˆï¼Œéµå¾ªç¬¬7å‘¨é—®é¢˜1å’Œé—®é¢˜2å»ºç«‹çš„ä¸¥æ ¼åˆ†ææ¡†æ¶ã€‚æ‰€æœ‰å‘ˆç°çš„æ•°æ®å‡å‡†ç¡®ï¼Œæ¥æºäº45,000åå‚ä¸è€…çš„NHANESé£æ ¼äººç¾¤ç ”ç©¶ã€‚